Harvard center for cancer prevention purchases Pyrosequencing's psq96 system for dna analysis

HARVARD CENTER FOR CANCER PREVENTION PURCHASES PYROSEQUENCING'S PSQ 96 SYSTEM FOR DNA ANALYSIS Uppsala, Sweden, November 21, 2000- Pyrosequencing AB (SSE:PYRO A), a developer, manufacturer and marketer of DNA sequencing systems for applied genetic analysis, announced that Harvard Center for Cancer Prevention has purchased the Company's PSQ 96 System. Harvard will use the PSQ 96 System, which is based on the Company's Pyrosequencing sequencing by synthesis technology, to examine genetic variation in sample populations and correlate this information with risk factors for specific diseases such as cancer. "Associating genetic mutations or SNPs with certain cancers will provide key information in understanding the disease process and give us important insights for prevention and treatment," said Dr. David Hunter, Director, Harvard Center for Cancer Prevention. "Pyrosequencing's PSQ 96 System performs a unique 'sequencing by synthesis' analysis which should help us identify which SNPs are significant. We will relate this information to specific risk factors for the diseases we are studying which include colon and breast cancer." Pyrosequencing's PSQ 96 System performs accurate, reproducible SNP analysis, and is the first commercially available dedicated sequencing- based system for applied genetic analysis. Based on the Company's patented Pyrosequencing@ technology, the product provides rapid genetic analysis and offers a high capacity, cost-effective solution for SNP analysis and Tag sequencing- the analysis of short DNA sequences used for genetic identification. PSQ 96 Systems, launched earlier this year, include a sequencing instrument, software, and reagent kits necessary to conduct SNP analysis. "We are delighted that Harvard Center for Cancer Prevention has chosen our PSQ 96 System to advance their research in cancer and other important diseases," commented Erik Wallden, President and CEO of Pyrosequencing AB. "Our instruments and reagents continue to gain broad acceptance among the world's leading academic institutions and we believe that our approach will be the new standard in applied genetic analysis." In addition to Harvard Center for Cancer Prevention, the Company's academic and research clients include the Karolinska Institute, the National Institutes of Health, the National Cancer Center of Tokyo, and the University of California at Davis. Pyrosequencing's systems are also used by leading pharmaceutical, genomics and agbio companies. Pyrosequencing AB develops, manufactures and sells complete applied genetic analysis systems based on its Pyrosequencing@ technology, a simple-to-use DNA sequencing technique for accurate and consistent analysis. In the post-genome era, Pyrosequencing's technology addresses the increasing demand for applied genetic analysis across various markets, including research and routine clinical testing, as well as large-scale customized industrial applications, such as drug development by pharmaceutical companies. The Company's growing list of customers includes CuraGen Corporation, DuPont Agriculture, SmithKline Beecham, and the National Institutes of Health. The Company is headquartered in Uppsala, Sweden with North American operations located in Massachusetts. Pyrosequencing AB also has sales offices and distribution partners in Scandinavia, United Kingdom, Germany, BeNeLux, Switzerland and Japan. Pyrosequencing AB is listed on the OM Stockholm Exchange. The Company's Web site is WWW.PYROSEQUENCING.COM Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Pyrosequencing's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors FOR FURTHER INFORMATION CONTACT: Pyrosequencing AB Erik Walldén Theresa McNeely, Sr. Director President & CEO Investor and Public Relations erik.wallden@pyrosequencing.com tmcneely@pyrosequencing.com Phone: +46 18 565902 or 070-326 98 70 Phone: +1 508 389 9911 X106 ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/11/21/20001121BIT00580/bit0001.doc http://www.bit.se/bitonline/2000/11/21/20001121BIT00580/bit0002.pdf